×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PRTA – prothena corporation plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PRTA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
08:19 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock, down previously from $84.00.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock, down previously from $84.00.
12/20
08:16 am
prta
Prothena Co. plc (NASDAQ: PRTA) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock.
12/19
12:57 pm
prta
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.
12/19
08:32 am
prta
Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug [Seeking Alpha]
High
Report
Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug [Seeking Alpha]
12/19
01:08 am
prta
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]
High
Report
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]
12/19
01:05 am
prta
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
High
Report
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
11/20
12:04 am
prta
Prothena Co. plc (NASDAQ: PRTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/13
10:08 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:05 pm
prta
prothena corporation plc - ordinary shares
BEAT
Report
-0.7%
prothena corporation plc - ordinary shares
8/8/2024
04:05 pm
prta
prothena corporation plc - ordinary shares
BEAT
Report
4.4%
prothena corporation plc - ordinary shares
5/8/2024
04:05 pm
prta
prothena corporation plc - ordinary shares
MISS
Report
-4.5%
prothena corporation plc - ordinary shares
2/15/2024
04:05 pm
prta
prothena corporation plc - ordinary shares
MISS
Report
-1.8%
prothena corporation plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
01:24 pm
prta
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Medium
Report
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/13
07:01 am
prta
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: Fennell Todd W.
Low
Report
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: Fennell Todd W.
11/13
06:07 am
prta
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: SCULLY WILLIAM P
Low
Report
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: SCULLY WILLIAM P
11/12
04:10 pm
prta
Form 8-K PROTHENA CORP PUBLIC For: Nov 12
Low
Report
Form 8-K PROTHENA CORP PUBLIC For: Nov 12
11/12
04:02 pm
prta
Form 10-Q PROTHENA CORP PUBLIC For: Sep 30
Low
Report
Form 10-Q PROTHENA CORP PUBLIC For: Sep 30
11/8
10:47 am
prta
Form SC 13G PROTHENA CORP PUBLIC Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G PROTHENA CORP PUBLIC Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/7
09:34 am
prta
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: WELLINGTON MANAGEMENT GROUP LLP
Medium
Report
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: WELLINGTON MANAGEMENT GROUP LLP
10/18
10:55 am
prta
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: STATE STREET CORP
Low
Report
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: STATE STREET CORP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/19
Form 8-K Prothena Corp plc For: Dec 19
23.2%
3/19 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 15.7%
4/22 BRIEF-Prothena Corporation Plc- Update On Prasinezumab Expected Later This Year [Reuters] 15.5%
4/3 Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 14.7%
3/3 Prothena Announces Appointment of Brandon Smith as Chief Business Officer 6.9%
11/19 Prothena Co. PLC (NASDAQ: PRTA) was upgraded by analysts at Evercore ISI to an "outperform" rating. 5.5%
8/5 Form SC 13G Prothena Corp plc Filed by: GREAT POINT PARTNERS LLC 4.9%
10/30 Form 8-K/A Prothena Corp plc For: Oct 29 4.8%
5/7 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.600 ActVsEst 0.080 - Beat 4.8%
12/21 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 4.4%
3/19 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 15.7%
4/22 BRIEF-Prothena Corporation Plc- Update On Prasinezumab Expected Later This Year [Reuters] 15.5%
4/3 Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 14.7%
3/3 Prothena Announces Appointment of Brandon Smith as Chief Business Officer 6.9%
11/19 Prothena Co. PLC (NASDAQ: PRTA) was upgraded by analysts at Evercore ISI to an "outperform" rating. 5.5%
8/5 Form SC 13G Prothena Corp plc Filed by: GREAT POINT PARTNERS LLC 4.9%
10/30 Form 8-K/A Prothena Corp plc For: Oct 29 4.8%
5/7 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.600 ActVsEst 0.080 - Beat 4.8%
12/21 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 4.4%
TOP News Decliners
5/10
Prothena (PRTA) Investor Presentation - Slideshow [Seeking Alpha]
-7.4%
8/15 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -6.7%
8/30 Prothena: Trading Below Cash, Key Clinical Readouts In Coming Year [Seeking Alpha] -5.4%
7/30 Prothena to Report Second Quarter 2019 Financial Results on August 6 -4.8%
2/14 Form SC 13G/A Prothena Corp plc Filed by: GREAT POINT PARTNERS LLC -4.8%
2/12 Q4/2019 12/31/2019 EPS -0.540 ZacksConsensus -0.650 ActVsEst 0.110 - Beat -4.4%
11/5 Form 8-K Prothena Corp plc For: Nov 05 -4.2%
4/21 Prothena Co. PLC (NASDAQ: PRTA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -4.1%
1/23 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -3.7%
5/22 Form S-3 Prothena Corp plc -3.1%
8/15 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -6.7%
8/30 Prothena: Trading Below Cash, Key Clinical Readouts In Coming Year [Seeking Alpha] -5.4%
7/30 Prothena to Report Second Quarter 2019 Financial Results on August 6 -4.8%
2/14 Form SC 13G/A Prothena Corp plc Filed by: GREAT POINT PARTNERS LLC -4.8%
2/12 Q4/2019 12/31/2019 EPS -0.540 ZacksConsensus -0.650 ActVsEst 0.110 - Beat -4.4%
11/5 Form 8-K Prothena Corp plc For: Nov 05 -4.2%
4/21 Prothena Co. PLC (NASDAQ: PRTA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -4.1%
1/23 Prothena Co. PLC (NASDAQ: PRTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -3.7%
5/22 Form S-3 Prothena Corp plc -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: